Lexicon Pharmaceuticals, Inc.

NASDAQ:LXRX

Biotechnology

Healthcare
$1.72 -2.64%

-$0.05 today

Market cap
$765.80M
Beta
1.07
P/E (TTM)
-30.5
EPS (TTM)
-$0.07
52W Low $0.71High $2.53

Volume 2.02M

Average 2.48M

Income Statement

Follow revenue through to earnings.

Revenue

$49.80M

FY 2025 · Annual

+60.2% YoY

Operating Income

-$48.91M

FY 2025 · Annual

Net Income

-$50.34M

FY 2025 · Annual

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue298K139K1.2M31.08M49.8M
Cost of Revenue55.05M52.52M58.97M616K274K
Gross Profit(54.75M)(52.38M)(57.77M)30.47M49.53M
Gross Margin-18371.8%-37681.3%-4798.0%98.0%99.4%
Research & Development55.05M52.82M58.89M84.48M61.12M
Selling, General & Admin000131.9M37.32M
Operating Expenses32.34M48.38M113.98M227.58M98.44M
Depreciation & Amortization292K427K554K534K621K
EBITDA(86.66M)(100.03M)(169.76M)(184.29M)(41.38M)
EBITDA Margin-29081.9%-71966.2%-14099.3%-592.9%-83.1%
Operating Income(87.09M)(100.76M)(171.75M)(197.12M)(48.91M)
Operating Margin-29224.8%-72489.2%-14265.0%-634.2%-98.2%
Interest Income134K1.6M7.73M12.29M6.91M
Interest Expense802K2.78M13.1M15.58M8.34M
Other Income / Expenses(668K)(1.18M)(5.37M)(3.29M)(1.43M)
Income Before Tax(87.76M)(101.94M)(177.12M)(200.4M)(50.34M)
Pre-Tax Margin-29449.0%-73341.0%-14710.9%-644.8%-101.1%
Income Tax Expense00000
Net Income(87.76M)(101.94M)(177.12M)(200.4M)(50.34M)
Net Margin-29449.0%-73341.0%-14710.9%-644.8%-101.1%
EPS (Basic)(0.61)(0.62)(0.80)(0.63)(0.14)
EPS (Diluted)(0.61)(0.62)(0.80)(0.63)(0.14)
Weighted Avg Shares145.65M165.73M221.13M320.03M363.05M
Weighted Avg Shares (Diluted)145.65M165.73M221.13M320.03M363.05M

LXRX Earnings Waterfall · TTM

NASDAQ:LXRX · Revenue to Net Income

Key Ratios

EPS$-0.07
Gross Margin98.2%
Net Margin-91.6%
P/E Ratio-34.9
P/S Ratio38.0

Analysis

$69.6M of revenue converted into -$26.1M of net income for the selected period. Gross margin is 98.2% and net margin is -91.6%, showing how much revenue survives after costs and taxes. EPS is $-0.07, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
4Statement of changes in beneficial ownershipNov 9, 2026
SC 13G/ASC 13G/A filingNov 5, 2026
10-QQuarterly reportNov 5, 2026
8-KCurrent reportNov 5, 2026
EFFECTEFFECT filingAug 14, 2026

How much revenue does LXRX generate?

Lexicon Pharmaceuticals, Inc. (LXRX) reported $49.80M of revenue in fiscal 2025.

Is LXRX profitable?

Lexicon Pharmaceuticals, Inc. (LXRX) reported -$50.34M of net income, with a net margin of -101.1%.